An open-label, Multinational, Phase IIIb Study to Evaluate Patient and Satisfaction, Safety and Efficacy of Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer (ML28851) in Adjuvant/Neo-Adjuvant Setting